<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02506933</url>
  </required_header>
  <id_info>
    <org_study_id>14295</org_study_id>
    <secondary_id>NCI-2015-01228</secondary_id>
    <secondary_id>14295</secondary_id>
    <secondary_id>R01CA077544</secondary_id>
    <nct_id>NCT02506933</nct_id>
  </id_info>
  <brief_title>Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant</brief_title>
  <official_title>A Phase II Randomized, Placebo-Controlled, Multicenter Trial to Evaluate the Protective Function of a CMV-MVA Triplex Vaccine in Recipients of an Allogeneic Hematopoietic Stem Cell Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>City of Hope Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Diavax Biosciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>City of Hope Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II trial studies the safety and how well multi-peptide cytomegalovirus
      (CMV)-modified vaccinia Ankara (MVA) vaccine works in reducing CMV complications in patients
      previously infected with CMV and are undergoing a donor hematopoietic cell transplant. CMV is
      a virus that may reproduce and cause disease and even death in patients with lowered immune
      systems, such as those undergoing a hematopoietic cell transplant. By placing 3 small pieces
      of CMV deoxyribonucleic acid (DNA) (the chemical form of genes) into a very safe, weakened
      virus called MVA, the multi-peptide CMV-MVA vaccine may be able to induce immunity (the
      ability to recognize and respond to an infection) to CMV. This may help to reduce both CMV
      complications and reduce the need for antiviral drugs in patients undergoing a donor
      hematopoietic cell transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To evaluate the safety and tolerability of CMV-MVA Triplex (multi-peptide CMV-MVA vaccine)
      in vaccinated hematopoietic cell transplant (HCT) recipients by assessing the following:
      non-relapse mortality (NRM) at 100 days post HCT, severe (grade 3-4) acute graft-versus-host
      disease (GVHD) (aGVHD), and grade 3-4 adverse events (AEs) (Common Terminology Criteria for
      Adverse Events [CTCAE] 4.0) probably or definitely related to the vaccination within 2 weeks
      from each vaccination.

      II. To determine if CMV-MVA Triplex reduces the frequency of CMV events defined as
      reactivation or CMV disease in allogeneic CMV positive HCT recipients (HCT-R+).

      SECONDARY OBJECTIVES:

      I. To characterize CMV reactivation and CMV disease in recipients of CMV-MVA Triplex compared
      to placebo by assessing time-to viremia (defined as number of days from transplantation to
      the date of &gt; 500 CMV gc/mL), duration of viremia, recurrence of viremia, incidence of late
      CMV viremia/disease (&gt; 100 and =&lt; 360 days post HCT), use of antiviral drugs (triggered by
      clinically significant viremia of &gt;= 1500 CMV gc/mL), cumulative number of CMV specific
      antiviral treatment days.

      II. To evaluate the impact of CMV-MVA Triplex on transplant related outcomes by assessing the
      incidence of acute GVHD (aGVHD), chronic GVHD (cGVHD), relapse, non-relapse mortality,
      all-cause mortality, infections.

      III. To determine 1) if CMV-MVA Triplex increases levels, function and kinetics of
      CMV-specific T cell immunity in vaccinated compared to placebo treated human leukocyte
      antigen (HLA) A*0201, CMV seropositive HCT-recipients, 2) to determine whether vaccination
      induces adaptive natural killer (NK) cell population changes, and increase in the highly
      cytotoxic memory killer cell lectin-like receptor subfamily C, member 2 (NKG2C)+ NK cells,
      and 3) to explore GVHD biomarkers and compare between the vaccine and placebo groups.

      OUTLINE: Patients are randomized to 1 of 2 arms.

      ARM I: Patients receive multi-peptide CMV-MVA vaccine intramuscularly (IM) on days 28 and 56
      post-HCT.

      ARM II: Patients receive placebo IM on days 28 and 56 post-HCT.

      After completion of study, patients are followed up for 1 year post-HCT.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>November 5, 2015</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CMV events encompassing any CMV reactivation &gt;= 500 CMV genome copies gc/mL, low-level reactivation prompting antiviral therapy, or CMV disease</measure>
    <time_frame>Prior to day 100 post-HCT</time_frame>
    <description>Vaccine and placebo groups will be compared with regard to the hazard of CMV events, using the Anderson-Gill approach to repeated events, as implemented in the R survival package. Power calculations are conservatively based only on binomial incident event rates.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of grade 3-4 severe adverse events (SAE) that are at least possibly attributed to the injection by the (masked) treating physician, assessed by CTCAE version 4.0</measure>
    <time_frame>Within 2 weeks of injection</time_frame>
    <description>Will be listed, with incidence compared by Fisher's exact test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of severe (grade 3-4) aGVHD</measure>
    <time_frame>Up to 100 days post-HCT</time_frame>
    <description>Will be summarized by Kaplan-Meier curves, and compared using the log-rank test.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>NRM</measure>
    <time_frame>At 100 days post-HCT</time_frame>
    <description>Will be summarized by arm as percentages, with exact binomial confidence bounds, and compared across arms using Fishers exact test.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Up to 1 year post-HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative number of CMV specific antiviral treatment days</measure>
    <time_frame>Up to 1 year post-HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of viremia</measure>
    <time_frame>Up to 1 year post-HCT</time_frame>
    <description>The total days on antivirals for CMV reactivation (induction, maintenance, and total) will be assessed for each individual, with arms compared using Wilcoxon's rank-sum test. Other characterizations of the duration of viremia and response to therapy will be descriptive in nature.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of aGVHD</measure>
    <time_frame>Up to 1 year post-HCT</time_frame>
    <description>The cumulative incidence of aGVHD will be estimated using Kaplan-Meier or Fine-Gray estimators, as appropriate, and compared using the log-rank test, or the corresponding subdistribution test due to Gray.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of cGVHD</measure>
    <time_frame>Up to 1 year post-HCT</time_frame>
    <description>The cumulative incidence of cGVHD will be estimated using Kaplan-Meier or Fine-Gray estimators, as appropriate, and compared using the log-rank test, or the corresponding subdistribution test due to Gray.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of infections</measure>
    <time_frame>Up to 1 year post-HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of late CMV viremia</measure>
    <time_frame>Up to 360 days post-HCT</time_frame>
    <description>Assessed between &gt; 100 days and =&lt; 360 days post-HCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levels and kinetics of CMV-specific T cell immunity</measure>
    <time_frame>Up to 1 year post-HCT</time_frame>
    <description>Will be combined with immunophenotyping and functional studies. The data analysis for estimating the effect of vaccination on cellular immunity will necessarily be more exploratory in nature. The longitudinal CMV-specific cellular assay data will be modeled on a logarithmic scale, using a generalized estimating equation approach to accommodate the stochastic dependence through time. This produces an estimated multiplicative effect of vaccination, qualified by a valid estimate of variability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NK phenotype and function (cytotoxicity and cytokine production)</measure>
    <time_frame>Up to 1 year post-HCT</time_frame>
    <description>The data analysis for estimating the effect of vaccination on cellular immunity will necessarily be more exploratory in nature. The longitudinal CMV-specific cellular assay data will be modeled on a logarithmic scale, using a generalized estimating equation approach to accommodate the stochastic dependence through time. This produces an estimated multiplicative effect of vaccination, qualified by a valid estimate of variability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NRM</measure>
    <time_frame>Up to 1 year post-HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival</measure>
    <time_frame>Up to 1 year post-HCT</time_frame>
    <description>The cumulative incidence of relapse-free survival will be estimated using Kaplan-Meier or Fine-Gray estimators, as appropriate, and compared using the log-rank test, or the corresponding subdistribution test due to Gray.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to engraftment, defined as the first of 3 consecutive days when the peripheral blood absolute neutrophil count is &gt;= 500/mm^3</measure>
    <time_frame>Up to 1 year post-HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to viremia, defined as number of days from transplantation to the date of &gt; 500 CMV gc/mL</measure>
    <time_frame>Up to 1 year post-HCT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of antiviral drugs, triggered by clinically significant viremia &gt;= 1500 CMV gc/mL</measure>
    <time_frame>Up to 1 year post-HCT</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive</condition>
  <condition>Acute Lymphoblastic Leukemia in Remission</condition>
  <condition>Acute Myeloid Leukemia in Remission</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive</condition>
  <condition>Cytomegaloviral Infection</condition>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Lymphadenopathy</condition>
  <condition>Lymphoblastic Lymphoma</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Myelofibrosis</condition>
  <condition>Myeloproliferative Neoplasm</condition>
  <condition>Non-Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm I (multi-peptide CMV-MVA vaccine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive multi-peptide CMV-MVA vaccine IM on days 28 and 56 post-HCT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive placebo IM on days 28 and 56 post-HCT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (multi-peptide CMV-MVA vaccine)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Multi-peptide CMV-Modified Vaccinia Ankara Vaccine</intervention_name>
    <description>Given IM</description>
    <arm_group_label>Arm I (multi-peptide CMV-MVA vaccine)</arm_group_label>
    <other_name>CMV-MVA Triplex Vaccine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Given IM</description>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <other_name>placebo therapy</other_name>
    <other_name>PLCB</other_name>
    <other_name>sham therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All subjects must have the ability to understand and the willingness to sign a written
             informed consent

          -  Participant must be willing to comply with study and/or follow-up procedures,
             including willingness to be followed for one year post-HCT

          -  Planned HCT for the treatment of the following hematologic malignancies:

               -  Lymphoma (Hodgkin and Non-Hodgkin)

               -  Myelodysplastic syndrome

               -  Acute lymphoblastic leukemia in first or second remission (for acute
                  lymphoblastic leukemia/lymphoblastic lymphoma, the disease status must be in
                  hematologic remission by bone marrow and peripheral blood; persistent
                  lymphadenopathy on computed tomography [CT] or CT/positron emission tomography
                  (PET) scan without progression is allowed)

               -  Acute myeloid leukemia in first or second remission

               -  Chronic myelogenous leukemia in first chronic or accelerated phase, or in second
                  chronic phase

               -  Other hematologic malignancies including chronic lymphocytic leukemia,
                  myeloproliferative disorders and myelofibrosis; patients with multiple myeloma
                  and those with non-malignant disease such as aplastic anemia are excluded

               -  Patients undergoing a second allogeneic (allo) HCT are not eligible (patients who
                  have undergone a previous autologous HCT are eligible)

          -  CMV seropositive (recipient)

          -  Planned related or unrelated HCT, with 8/8 (A,B,C,DRB1) high/intermediate resolution
             HLA donor allele matching

          -  Planned HCT with minimal to no-T cell depletion of graft

          -  Conditioning and immunosuppressive regimens according to institutional guidelines are
             permitted

          -  Negative serum or urine beta-human chorionic gonadotropin (HCG) test (female patient
             of childbearing potential only) within two weeks of registration

          -  Seronegative for human immunodeficiency virus (HIV), hepatitis C virus (HCV) and
             active hepatitis B virus (HBV) (surface antigen negative) within 2 months of
             registration

          -  Agreement by females of childbearing potential and sexually active males to use an
             effective method of contraception (hormonal or barrier method of birth control or
             abstinence) prior to study entry and for up to 90 days post-HCT; should a woman become
             pregnant or suspect that she is pregnant while participating on the trial, she should
             inform her treating physician immediately

        Exclusion Criteria:

          -  Any prior investigational CMV vaccine

          -  Experimental anti-CMV chemotherapy in the last 6 months

          -  Live attenuated vaccines

          -  Medically indicated subunit (Engerix-B for HBV; Gardasil for human papillomavirus
             [HPV]) or killed vaccines (e.g. influenza, pneumococcal, or allergy treatment with
             antigen injections)

          -  Allergy treatment with antigens injections

          -  Alemtuzumab or any equivalent in vivo T-cell depleting agent

          -  Antiviral medications with known therapeutic effects on CMV such as ganciclovir
             (GCV)/valganciclovir (VAL), foscarnet (FOS), Cidofovir, CMX-001, maribavir; acyclovir
             has no known therapeutic efficacy against CMV and is allowable as standard of care to
             prevent herpes simplex virus (HSV)

          -  Prophylactic therapy with CMV immunoglobulin or prophylactic antiviral CMV treatment

          -  Other investigational product â€” concurrent enrollment in other clinical trials using
             any investigational new drug (IND) drugs with unknown effects on CMV or with unknown
             toxicity profiles is prohibited

          -  Other medications that might interfere with the evaluation of the investigational
             product

          -  Patients with active autoimmune conditions requiring systemic immunosuppressive
             therapy within the previous 5 years are not eligible

          -  Pregnant women and women who are lactating; breastfeeding should be discontinued if
             the mother is enrolled on this study

          -  Any other condition that would, in the Investigator's judgment, contraindicate the
             patient's participation in the clinical study due to safety concerns or compliance
             with clinical study procedures, e.g., social/ psychological issues, etc

          -  Prospective participants who, in the opinion of the investigator, may not be able to
             comply with all study procedures (including compliance issues related to
             feasibility/logistics)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryotaro Nakamura, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>City of Hope Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2015</study_first_submitted>
  <study_first_submitted_qc>July 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2015</study_first_posted>
  <last_update_submitted>May 4, 2018</last_update_submitted>
  <last_update_submitted_qc>May 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Leukemia, Myeloid, Chronic-Phase</mesh_term>
    <mesh_term>Leukemia, Myeloid, Accelerated Phase</mesh_term>
    <mesh_term>Lymphadenopathy</mesh_term>
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

